Arrowhead Pharmaceuticals, Inc.
$71.64
▲
0.83%
2026-04-22 10:12:13
arrowheadpharma.com
NMS: ARWR
Explore Arrowhead Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$10.05 B
Current Price
$71.64
52W High / Low
$76.76 / $10.92
Stock P/E
46.54
Book Value
$4.14
Dividend Yield
—
ROCE
8.27%
ROE
75.5%
Face Value
—
EPS
$1.54
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
711
Beta
1.27
Debt / Equity
124.07
Current Ratio
3.38
Quick Ratio
4.86
Forward P/E
-15.16
Price / Sales
8.36
Enterprise Value
$8.9 B
EV / EBITDA
27.33
EV / Revenue
8.16
Rating
Buy
Target Price
$81.09
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Return on equity is on the weaker side.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
| 2. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
| 3. | Jyong Biotech Ltd. | $2.31 | — | $185.51 M | — | 35.69% | 8.55% | $67 / $1.43 | $-0.31 |
| 4. | Alector, Inc. | $2.71 | — | $298.53 M | — | -69.73% | -1.82% | $3.4 / $0.9 | $0.28 |
| 5. | Protalix BioTherapeutics, Inc. | $2.27 | — | $184.11 M | — | -9.85% | -14.44% | $3.19 / $1.32 | $0.6 |
| 6. | Caris Life Sciences, Inc. | $21.24 | — | $5.98 B | — | 4.52% | -45.37% | $42.5 / $16.28 | $2.04 |
| 7. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 264.03 M | 256.47 M | 27.77 M | 542.71 M | 2.5 M |
| Operating Profit | 40.81 M | 44.11 M | -165.55 M | 381.2 M | -161.41 M |
| Net Profit | 30.81 M | -23.75 M | -175.24 M | 370.44 M | -173.09 M |
| EPS in Rs | 0.22 | -0.17 | -1.25 | 2.65 | -1.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 829.45 M | 3.55 M | 240.74 M | 243.23 M |
| Operating Profit | 98.35 M | -601.08 M | -205 M | -178.51 M |
| Net Profit | -1.63 M | -599.49 M | -205.28 M | -176.06 M |
| EPS in Rs | -0.01 | -4.28 | -1.47 | -1.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.39 B | 1.14 B | 765.55 M | 691.94 M |
| Total Liabilities | 881.88 M | 948.74 M | 478.39 M | 273.6 M |
| Equity | 466.05 M | 185.44 M | 271.34 M | 398.52 M |
| Current Assets | 950.64 M | 695.47 M | 416.47 M | 405.3 M |
| Current Liabilities | 195.49 M | 103.17 M | 105.46 M | 138.85 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 179.55 M | -462.85 M | -153.89 M | -136.13 M |
| Investing CF | -129.29 M | -420.07 M | -96.16 M | -5.42 M |
| Financing CF | 74.01 M | 870.52 M | 253.05 M | 65.19 M |
| Free CF | 156.89 M | -604.32 M | -330.63 M | -188.91 M |
| Capex | -22.67 M | -141.47 M | -176.74 M | -52.78 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -98.52% | -1.03% | — | — |
| Earnings Growth % | -192.04% | -16.59% | — | — |
| Profit Margin % | -16882.37% | -85.27% | -72.39% | — |
| Operating Margin % | -16927.06% | -85.16% | -73.39% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -15812.81% | -72.97% | -66.72% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.